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Cancerdevelopment in man appeared tobe amultistage process as suggestedbyepidemiological studies on
commonlyoccurringgastric,colon,andbreastcancersandalsoonhumanretrovirus-relatedleukemia,andby
the finding by physicians and surgeons ofprecancerous lesions for many types ofneoplasias. In the last 10
years it has become evident that human cancers have multiple genetic alterations causedbypoint mutations,
recombinations, amplifications, and/or deletions. The genes affected include both oncogenes and tumor-
suppressor genes and genes that accelerate cell proliferation and metastasis. Cancers with more malignant
properties and poorer prognosis are generally associated with larger numbers ofgenetic alterations. These
multiple genetic alterations are considered to be a direct reflection of the multiple steps involved in
carcinogenesis. The multiple genetic alterations are caused by multiple environmental carcinogenic sub-
stances or factors, each ofwhich usually exists only at minute concentrations and does not exert any major
impact alone except under particular occupational, iatrogenic, and locally geographic conditions. The fact
thatcarcinogenesis is amultistep process involvingmultiple geneticalterationsclearlyneedstobetaken into
consideration in assessing the risks of environmental carcinogenic substances or factors. The increasing
incidence ofmultiple primary cancers is also most easilyunderstood from theviewpoint ofmultiple steps in
carcinogenesis.Possiblemultipleapproachestocancerpreventionshouldthereforebeconsideredinrelationto
multistep carcinegenesis and multiple carcinogenic factors.
Introduction
The existence of multiple steps in carcinogenesis was
predicted by Rous and his associates from careful obser-
vations in animal experiments almost a half century ago
(1). Armitage and Doll also reached the same conclusion
from analysis ofthe age distributions of common cancers
in humans in 1954 (2). More recently, it was similarly
suggested on the basis of age distribution ofpatients that
several events are required between initial HTLV-1 infec-
tionandonsetofadultT-cellleukemia(ATL) (3).Moreover,
two-step carcinogenesis in the dorsal skin of mice by a
single application of a limited amount of carcinogenic
polycyclic aromatic hydrocarbon followed by repeated
application of croton oil was demonstrated by Berenblum
and Shubik in 1947 (4).
The importance ofgenetic alterations in somatic cells in
cancer development was described by Bauer in 1928 (5).
However, in 1914 Boveri predicted the function of onco-
genes, using the term "chromosomes which promote divi-
sion," and the inactivation of tumor-suppressor genes by
saying that "inhibition chromosomes were eliminated" in
'National Cancer Center Research Institute, 1-1, TsukiJi 5-chome,
Chuo-ku, Tokyo 104, Japan.
Address reprint requests to T. Sugimura, National Cancer Center
Research Institute, 1-1, Tsukii 5-chome, Chuo-ku, lbkyo 104, Japan.
his book (6). In the last 20 years, molecular biological
studies have clearly revealed the existence of many
oncogenes and tumor-suppressor genes and their respec-
tive activation and inactivation among many types of
cancers.
Multiple Genetic Alterations
The occurrence of more than one alteration of cancer-
related genes, namely, N-ras activation and c-myc ampli-
fication in cultured HL-60 cells, was first observed by
Weinberg and associates (7). Subsequently, Taya et al.
demonstrated K-rasmutation andc-mycamplification in a
human lunggiant-cell carcinoma, Lu-65 (8). Yamada etal.
firstdemonstrated thecoexistence ofamutation in K-ras,
amplification ofmutated K-ras, andamplification ofc-myc
in human pancreatic cancer without passing through cell
culture (9). Lossofheterozygosity(LOH) ofchromosomes
3p, 13q, and 17p was first observed by Yokota et al. in
human small-cell lung cancers (10). The genes responsible
for the alterations of chromosomes 13q and 17p were the
Rb andp53 genes, respectively, while that on chromosome
3pwas suggested to be a gene for a receptor-type protein
tyrosine phosphatase -y (11), although the possible contri-
bution ofother genes was also envisaged.Vogelstein etal.
demonstrated theinvolvement ofmultiple genes in human
colon carcinogenesis, detecting point mutations of K-ras,SUGIMURA ET AL.
N-ras, andallelic deletionofchromosomes5q, 17p, and18q
(12). The development of convenient laboratory methods
suchas RFLP [restriction fragmentlengthpolymorphism
(13)], PCR [polymerase chain reaction (14)], and SSCP
[single-strand conformation polymorphism (15)] analyses
has greatly facilitated accumulation of information on
multiple genetic alterations in various types of human
cancers. Indeed, application of these techniques to small
amounts of clinical materials has opened a new field of
clinical molecular pathology. As a result there are now
more than 50 reports available on multiple genetic altera-
tions in human cancers (16).
Multistep Carcinogenesis
Fearon and Vogelstein reported the accumulation of
genetic alterations during human colorectal carcino-
genesis documenting the presence ofmultiple steps atthe
molecular level (17). The involvement ofa gene on chromo-
some 5q in familial polyposis of the colon was first
reported byBodmer's group (18). Duringinvivo progress
from normal epithelium to hyperproliferation epithelium,
early adenoma, intermediate adenoma, late adenoma, and
carcinoma sequence, the frequencies of LOH of chromo-
some 5q, K-ras activation, and LOHs of chromosomes of
17p and 18q increase (17). The gene on chromosome 18q
wasidentifiedby Fearon etal. as DCC (deleted in colorec-
tal cancer), which encodes for a cell adhesion protein (19).
Morerecently,alteredgenesonchromosome5wereidenti-
fied as MCC (mutated in colorectal cancer) and APC
(adenomatous polyposis coli) by Vogelstein's (20,21),
Nakamura's (22), and White's (23,24) laboratories.
Thmor growth is thought to be monoclonal, originating
from a single cell. This was difficult to prove in human
cancers in vivo, but Tsuda et al. confirmed it using sur-
gicallyresectedhepatocellular carcinomas (25).Theywere
able to obtain many specimens of early hepatocellular
carcinomas that were surgically removed from patients
diagnosed by a recently developed ultrasonic system for
tumor detection. The hepatitis B virus genome integrates
into the genome ofhepatic cells atrandom sites, but DNA
isolated from hepatomas of different patients and from
different foci inindividual patients gave separate, distinct
signals for integration site bands (25-27). In addition,
Tsuda et al. succeeded in demonstrating a stepwise car-
cinogenic process in a nodule in which hepatocellular
carcinoma cells were clonally growing. For this, they
examined DNAofasmallnodulecomposed ofmoremalig-
nant cells in a nodule composed of less malignant cells.
This is known as a tumor within a tumor. DNA isolated
from both the peripheral, less malignant part and the
central, more malignant part showed the same single,
distinctive band of integrated HBV genome, whereas
DNA from the noncancerous portion surrounding the
nodule gave only a smearwith an HBVgenome on South-
ern blot analysis (25). In a hepatocellular nodule contain-
ing two small nodules composed ofmore malignant cells,
the DNAofthese twomalignantcarcinomas both showed
mutations ofp53 genes, but in different exons. Further-
more, mutations of p53 genes were not observed in the
peripheral, lessmalignantparts (Oda and Hirohashi, per-
sonal communication). In hepatocellular carcinomas, fre-
quencies ofLOHsonchromosomes4,16q,and17pincrease
in general with the acquisition of more malignant phe-
notypes; i.e., fromearly,well-differentiated, throughmod-
erately differentiated to poorly differentiated lesions (28).
There is much circumstantial evidence that amplifica-
tions ofvarious genes accumulate duringthelatephase of
carcinogenesis. Chromosomal aberrations are also often
foundinclinicallyadvancedcasesofcancers.Amplification
of multidrug-resistance genes is an example of further
genetic alteration after establishment ofmalignancy (29).
Genetic alterations are often found more frequently in
metastatic foci than in primary tumors (10), and several
genes have been proposed as being causally related to
metastasis (30). Genomic instability would be expected to
play a role in more rapid accumulation offurther genetic
alterations. A genetic alteration resulting in genomic
instability, which might correspond to mutator mutations
inmicrobialgenetics(31),wouldbecrucialinhumancarcino-
genesis and could be called a "carcinogenizer mutation."
Specificity in Genetic Alterations with
Regard to Organs, Histopathology,
and Clinical Stages of Human Cancers
Genetic alterations show some specificities depending
ontheorganoforigin,histopathology, andclinicalstageof
cancers. For example, K-ras mutations are known to be
common in pancreatic and colon cancers, but not in breast
and liver carcinomas (32). The c-erbB-2 oncogene is often
amplified inintestinal-type adenocarcinomas ofthe stom-
ach, but not in scirrhous-type malignant lesions in the
same organ (33). The K-sam oncogene, encoding a
tyrosine kinase receptor, is amplified in scirrhous-type
adenocarcinomas, signet-ring-cell carcinomas, and mu-
cinous adenocarcinomas, but not in the intestinal type of
stomach cancer (34,35). This K-sam gene was originally
isolated as an amplified gene in KATO III cells, derived
from a signet-ring-cell carcinoma ofthe stomach (34,36).
In 50% ofthe esophageal cancers and 15% ofthe breast
cancersexamined, thechromosome11q13locus, containing
theHST1 and INT2 genes, was found to be amplified, but
almost none were found in the stomach cancers (37,38).
Studyofmolecularmechanismsunderlyinggeneticaltera-
tion is important for establishing etiology of cancers
among various organs.
Information on specificities of multiple genetic altera-
tions should thus provide clues as to why cancer develop-
mentoccursinparticularorgans. Forinstance, analysisof
mutation site and base change for hepatomas in aflatoxin
Bl-contaminated and noncontaminated areas suggested
different patterns in the mechanism of mutation in p53
genes (39,40). Interestingly, cholangiocarcinomas in Ja-
pan are frequently associated with K-ras activation, but
those in Thailand, which resulted in part from liver fluke
infection, have no K-ras mutation, whereas both showthe
same frequency of mutation of the p53 gene (Tsuda and
Hirohashi, unpublished data).
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Multiple Environmental Carcinogens,
Carcinogenic Factors, and
Carcinogenic Conditions
The multiple genetic alterations in carcinomas are pre-
sumably caused by multiple kinds of environmental
xenobiotics and autobiotics. Asxenobiotics, polycyclic aro-
matichydrocarbons,N-nitrosamines,mycotoxins, andhet-
erocyclic amines are typical genotoxic carcinogens.
However, the extent of exposure to any one ofsuch chemi-
cals is generally thought to be very small in comparison
withtheireffective dosesforproducing cancers inrodents
in standard long-term carcinogenesis experiments. It
should be true for exposures to ionizing radiation and
ultraviolet light. Autobiotic genotoxic agents such as oxy-
gen radicals can also modify DNA bases, as represented
bythe formation of8-hydroxyguanine and thymine glycol
(41,42). In addition, nitric oxide synthase produces NO
from L-arginine, this NO being involved in endogenous
formation of nitrosamine compounds (43-45) as well as
inducing deamination of 5-methylcytosine residues of
DNAto produce thymine residues, resulting in transition
of C to T after replication of DNA (46). With all the
compounds described above as examples, DNAdamage is
caused, which could lead to genetic alteration in somatic
cells.
ThefidelityofDNAreplication andequaldistribution of
the genome between daughter cells both involve some
possibility of genetic alterations, and cell proliferation
itselfmight be expected to increase the chances of'thege
genetic alterations occurring. Cell turnover in healthy
resting-cell populations can be induced by viral or bac-
terial infection, mechanical tissue damage, and inflamma-
tory reactions. The structure of the hepatitis C virus
(HCV) was recently fully elucidated (47,48), and HCV
infection causes chronic hepatitis associatedwith death of
hepatic cells and their compensatory regeneration. How-
ever, genomic integration ofthe HCV genome has not so
far been observed. Instead, hepatic cells that undergo
manygenerationsthroughrepeatedcelldivisions are more
likely to accumulate genetic alterations by chance. This
condition could be termed "local aging" or "topographic
senescence" limited to the liver, because in healthy adults,
hepatic cells rarely divide, probably once a year (49).
Hepatocytes that divide 30 times a year represent a
hepatic cellpopulation aging30 times fasterthan the liver
in healthy condition.
There is also a class ofnongenotoxic carcinogens called
tumorpromoters.Thebestknowntumorpromoteris12-0-
tetradecanoylphorbol-13-acetate(TPA), isolated from
croton oil. Other compounds with similar strong tumor-
promoting activity in two-step carcinogenesis experi-
ments in the dorsal skin ofmice have also been reported.
These areteleocidinfrom myceliaofStreptomycesmedio-
cidicus, lyngbyatoxin A from a blue-green alga, Lyngbya
majuscula and aplysiatoxin from a blue-green alga,
Lyngbya majuscula (50,51). All these tumor promoters
share the same surface receptors and activate protein
kinase C (51).
Okadaic acid, a polyether compound ofa C38 fatty acid
obtainedfromablacksponge,wasalsofoundtobeatumor
promoter in mouse skin experiments, having the same
potency as TPA (52). However, unlike TPA and teleocidin,
okadaic acid is apotentinhibitor ofproteinphosphatases,
modulating phosphorylation of intracellular proteins,
including some related to the cell cycle (53). All these tu-
mor promoters stimulate prostaglandin E2 synthesis (51).
TPA, teleocidin, lyngbyatoxin A, aplysiatoxin, and
okadaic acid are effective at microgram levels in car-
cinogenesis experiments when applied to mouse skin and
exertmanybiological activities invitro even atnanogram
levels. However, there is, ironically, no evidence that these
specifically functioning tumorpromoterswhich havebeen
most intensively studied in the international cancer
research community have, in fact, any relation to human
carcinogenesis, exceptforonepaperdescribing arelation-
ship between drinking bush tea and esophageal cancer in
Caribbean people (54).
More probably, common food components act as tumor
promoters. For example, sodium chloride might enhance
development ofgastric cancer through damage ofgastric
mucosa and production of chronic gastritis (55). In rat
experiments, sodium chloride is reported to show a pro-
moting effect in gastric carcinogenesis and to increase
levelsofmalondialdehydeinbothgastricmucosaandurine
(56,57). Higher fat intake should yield a tumor-promoting
condition for colon cancer development through more for
mation ofbile acid (58) and forbreast cancer development
throughincreasedgeneration ofestrogenbyaromatasein
adipose tissues (59).
Recently, Long-Evans rats with a cinnamonlike coat
color (LEC) were established. These LEC rats develop
hepatitis spontaneously at4 months old, and in those that
overcome the acute phase and survive with chronic hepa-
titis, hepatomas develop at 1-1.5 years of age without
exception (60). It was found that copper accumulates in
their livers and causes cell death and compensatory
regeneration (61). It is probable that this excess copper
increases oxygenradicalproduction, therebycausingcon-
tinued turnover of hepatic cells and creating a favorable
environment for hepatocarcinogenesis. It is noteworthy
that hepatomas in LEC rats lack activation ofany ofthe
ras oncogenes (62).
Multiple Genetic Backgrounds
Among many reports of cancer-prone families, one of
theoldestrecordsisprobablythatofgastriccancersinthe
Napoleonfamily(63). Inxerodermapigmentosum,charac-
terizedbyadeficiencyinthemolecularmechanismofDNA
repairofpyrimidinedimersproducedbyUV,multiple skin
cancersdevelop onexposuretosunlight(64). Familial ade-
nomatouspolyposiscoli,Wilms'tumor,andretinoblastoma
families are also well documented as cases of neoplasia
with a genetic background, and the genes responsible for
these diseases haverecentlybeen identified (21,23,65-67).
Li Fraumeni syndrome is associated with a germ line
mutation in the p53 gene. The mutated sites are in the
region from amino acid codons 245 to 258 (68,69). Many
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othergenetic diseases, includingthe Lynch syndrome and
SBLA syndrome, have also been reported (70,71), but the
genes responsible forthese diseases have notbeen identi-
fied as yet. More or less nonspecific genetic abnormalities
may also be involved in cancer development in cancer-
pronefamilies, althoughthenatureoftheaffectedgenesin
cancer cells amongfamilies has notbeen completely eluci-
dated.
In addition to heriditaryalterations ofgenes in somatic
cells, host factors are also important. These include
genetic control of drug-metabolizing enzymes, such as
cytochrome P450 (72,73), genetic polymorphism of acety-
lating enzymes (74,75), and the genetic background of
histocompatibility (76).
Risk Estimation and Multiple
CarcinogenicSteps Involving
Multiple Genetic Alterations
Although evidence has been accumulating thatmultiple
carcinogenic steps and multiple genetic alterations are
involved in carcinogenesis, it has also become clear that
there are many carcinogens in the ordinary human
environment. Their number, especially of genotoxic car-
cinogens, is enormous, but each one is usually present at
onlyverylowlevels. Riskestimation onceseemedrelatively
simple andverypromising, butwithincreasing awareness
of the situation, assessment of actual risk has proved
complicated and difficult. Itisnowgenerallyacceptedthat
there must be many cells with some genetic alterations in
thebodiesofadultandagedpeople.Thenumberofgenetic
alterations may not be sufficient to yield fully malignant
cancercells,buttheaffectedpopulationscouldprobablybe
quite easily converted to malignant cells by additional
genetic lesions caused by environmental mutagens/car-
cinogens. The extent ofexposure to such compounds nec-
essary to convert these intermediate cells to malignant
cells wouldprobablybe much smaller than thatnecessary
to drive the whole process from a normal cell base level.
Various mathematical formulas have been proposed to
calculate increase in risk. For instance, assuming the
necessity of 10 genetic alterations for fully malignant
conversion, cells with 8 and 9 genetic alterations have,
respectively, 1 million and 1 billiontimeshighersensitivity
than normal to conversion to fully malignant cells by
further exposure to environmental mutagens/carcinogens
(Sakai et al., unpublished data). Cells with some, but not
sufficient, genetic alterations are called in clinical terms
precancerouscells,andregionscomposedofthesecellsare
called precancerous regions. Some ofthem, however, may
not be necessarily distinguishable from normal tissue in
their appearance.
Itis often claimed thatthe actualintake (exposure size)
of environmental mutagens/carcinogens is very small in
comparison with the dose necessary to induce tumors in
adult healthy rodents in long-term feeding experiments.
However,recentmolecularbiological studieshaverevealed
themonoclonal nature ofcarcinogenesis. Duringmonoclo-
nal growth of cells with some genetic alterations, addi-
tional genetic alterations occur. Iftumorcells reallyorigi-
nate from a single cell, the tumor risk depends on the
targetsize,namely,thecellnumberfromwhichthecancer
could originate. Cancer cells arise from a certain size of
stem cell population, and the number of these cells is
proportional to the total number of cells in the body. In
other words, the risk of cancer development probably
depends on the size of the body, or the total number of
cells. Ahuman weighs 102 orders (300 times) more than a
ratand103 orders (3000times)morethan amouse. There-
fore, at the same concentrations of environmental
carcinogens/mutagens, the human risk ofdeveloping can-
cercellsis102orders (300times)morethanfortheratand
103 orders (3000 times) more than for the mouse. More-
over, the normal lifespan ofman is about 50 times that of
rodents. Becausethemeangenerationtimeofcellsmaybe
almost the same in humans and rodents, the risk of
developing cancer cells may be 15,000 and 150,000 times
higher in humans than in rats and mice, respectively. The
above calculation is clearly based on oversimplifications,
but, if based on this calculation, the actual intake of
heterocyclic amines in cooked meat and fishbyhumans in
normal, daily life corresponds to the doses that are car-
cinogenic in rodents (77). This is true not only for hetero-
cyclic amines, but also for other environmental mutagens/
carcinogens including polycyclic aromatic hydrocarbons,
N-nitrosamines, andmycotoxins. Becauseoxygenradicals
mayplayanimportantrole (78),thespecificmetabolicrate
ofhumans, at30calories/g/day, aboutone-tenth ofthe 200
calories/g/day in mice (79), needs to be carefully consid-
eredtoexplaintheirdifferentcontribution tocancerdevel-
opment between humans and rodents.
The presence of many types of anticarcinogenic sub-
stances in diet also requires inclusion in real risk estima-
tion (80). These substances are antioxidants, retinoids,
indoles, aromatic isothiocyanates, and plant-originated
polyphenols. Consideration ofthesefactorsisimportantto
avoid overestimation of the risk of carcinogens. On the
otherhand, factors effecting tumorpromotion should also
not be overlooked. In the two-step initiation/promotion
experiments, the carcinogenic effect ofthe genotoxic sub-
stance 7,12-dimethylbenz[a]anthracene painted on mouse
skin could easily be enhanced about 100 times by subse-
quenttreatmentwithcrotonoiloritsactiveprinciple,TPA
(81). Similarpromotion was observed fortreatment ofthe
dorsal skin ofmice with a heterocyclic amine, 3-amino-i-
methyl-5H-pyrido[4,3-b]indole (Trp-P-2), and then TPA
(82).
Long-term experiments in animals on the effects of
coadministrations of various kinds of genotoxic car-
cinogens are difficult to conduct. Ito et al. devised a new
approach,"Ito'smethod,"formedium-termtestsusingthe
ratliver (83). Diethylnitrosamine treatment, partialhepa-
tectomy, and then administration of a test substance
results in the formation ofglutathione S-transferase pla-
cental form (GST-P)-positive foci in the liver, the number
and area of which can be measured using a color video
image processor. This method requires a shorter period
and fewer animals compared to long-term carcinogenesis
experiments and is useful for screening hepatocarcino-
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gens and their inhibitory substances and for estimating
risk ofcarcinogens. Ito et al. have used the method to ex-
amine the effects of combinations of five heterocyclic
amines each at 1/25 and 1/5 of their carcinogenic doses,
and found that in combination, these compounds exerted
additive effects (84). Probably many other carcinogens
present in minute amounts in our environment are acting
on our body in a similar way.
Another factor that requires consideration is the age at
which exposure takes place. Thus it should be mentioned
thatneonatalmice aremuch more sensitive toheterocyclic
amines than are adult mice (85).
Multiple Primary Cancers
Recently, the cure rate of cancer has markedly in-
creased, but second primary cancers often develop in
patients whose first primary cancer has been completely
cured. This secondprimary canceris not ametastasis or a
recurrence ofthe firstprimary cancer. Moreover, it is not
necessarily due to chemotherapy or radiotherapy of the
firsttumor. Furthermore, athirdprimary cancer appears
not rarely after cure of the second cancer and subse-
quently fourth and even fifth primary cancers have been
observed (86). The age ofonset ofthese primary cancers
increases with increase in their number. About 8% ofthe
patients being treated at the National Cancer Center
Hospital from 1962 to 1989 were cases of such multiple
primary cancer (87). Multiple primary cancer occurs
metachronously as described above. However, synchron-
ous multiple cancers are also often found in single organs
(also called multifocal cancers), such as thelung, stomach,
liver, prostate, or urinary bladder, as well as simul-
taneously in two or more organs. Atypical cause ofmulti-
ple primary cancers is exposure to cigarette smoke. For
example, there are noticeable linkages oflaryngeal cancer
with lung cancer and of pharyngeal cancer with esopha-
geal cancer (87). It seems likely that these cancers ofthe
respiratory and upper digestive tracts are due to heavy
exposure to cigarette tar, and manyothercellsinthe tract
should have some, but not sufficient, numbers of genetic
alterations for their conversion to cancer cells. These cells
could be buds or precursors of subsequent primary can-
cers. Multipleprimary cancers are not a newphenomenon,
but onlyrecently has attention been called from scientists
ofcancer-specializing institutes and hospitals and officers
in governmental agencies to this health issue. Serious
consideration of suitable methods to prevent cancers
includingmultiple primary cancers areurgentlyneededin
light current knowledge ofmultiple genetic alterations in
cancer cells and ofmultistep carcinogenesis.
MultipleApproachesfor
Cancer Prevention
As discussed above, there are multiple genetic altera-
tions, multiple carcinogenic steps, multiple environmental
factors, and multiple primary cancers. This means that
multiple approaches are not only necessary but also
possible for cancer prevention. As multiple carcinogenic
factors areinvolved, thereis no singleroyalroad to cancer
prevention. Theriskfactorforanysinglecompounddeter-
mined evenfromexhaustiveanimalexperimentsis hardto
apply in reality to humans. Even the background of the
human populations is highly heterogeneous, not only
geneticallybut also in cellular composition with regard to
somatic cells with previous genetic alterations. Moreover,
humans are exposed to many different types of car-
cinogenic factors simultaneously and/or successively.
Arealistic andpractical approachisto trytoreduce the
extentofexposureofhumanstocarcinogenicfactorsasfar
aspossible,unlessthis results in serious discomfortatthe
individual level or serious inconvenience atthe community
level, including economic burden to the nation. In the case
ofindividuals, educated individual decisionmaking should
be encouraged with acceptance, at their own risk, of
certain levels of exposure. In the case ofthe community,
well-balanced committees of aware scientists, realistic
economists, and critical sociopsychologists should decide
pragmatically on suitable measures to prevent cancers
without seriously affecting the development of societies,
eventhough such decisions maybethetargetsofidealistic
people. In otherwords, in some cases, itmaybe necessary
to accept the presence of minute amounts of some car-
cinogens in our environment.
In fact, there are many examples ofcarcinogens in our
ordinary, daily life that we must accept, irrespective of
whether we are conscious oftheir existence (88,89). Well-
known examples are aflatoxin B1 in peanuts and their
products and heterocyclic amines ubiquitously present in
cooked meat and fish. However, exposure to these com-
pounds could be reduced by more strict regulation of
aflatoxin B1 and by appropriate methods to lessen the
formation ofthelattercompoundsin cooked meatandfish
such as by use ofmicrowave ovens and bywrapping meat
and fish in aluminum foil to prevent charring. The avoid-
ance ofmeat and fish contactwith a naked flame and the
removal of charred areas are also effective for lessening
the intake ofheterocyclic amines.
In cases of cancers due to viral infection, block of the
route of viral infection is extremely useful: for instance,
stoppingbreastmilkfeedingforpreventingHTLV-1 infec-
tion, careful screening of donor blood for HBV and HCV,
andhygienic sexualintercourse forpreventing HPVinfec-
tion. In addition, vaccination is definitely an effective
approach.
Generallyspeaking, the holistic approaches toimprove-
ment oflifestyle are much more important than decreas-
ing the extent ofexposure to a single carcinogenic factor.
Forinstance, the prevalence ofgastric carcinomas, which
are still a main form of cancer in many countries of the
world,hasbeendecreasingmarkedlyinadvancedWestern
countries, indicating that it can indeed be prevented. In
countries where its prevalence is still high, avoidance ofa
high intake of sodium chloride, reductions in nitrite and
nitrate intake, the use of a refrigerator rather than food
preservatives, consumption of green-yellow vegetables
and fruit rich in vitamin C and carotenoids, and mainte-
nance ofhygienic oral and tooth conditions are all recom-
mendations requiring implementation. If Helicobacter
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pyroli can be proved more clearly to be related to gastric
carcinogenesis, as recently reported (90), effective meas-
ures should also be taken to eliminate this bacteria from
gastric gland crypts, although Helicobacteris opportunis-
tic and may reappear after antibiotic and other drug
treatment. Thus,therearemultiplepragmatic approaches
tocancerpreventionthatcouldbeadoptedbasedonrecent
findings regarding the multiple genetic alterations, multi-
ple steps, and multiple environmental factors involved in
carcinogenesis.
Epilogue
The realization that carcinogenesis involves multiple
genetic alterations of cells, multiple steps, and multiple
environmental factors has greatly enhanced our under-
standing of cancer cells and the cancer problem and has
also provided the rationale for realistic approaches to
cancer prevention. An important point to be considered is
the impact of information on multiple genetic alterations
and multiple carcinogenic steps on cancer therapy. There
should be many target molecules for cancer drugs (91).
Remedy for one among many genetic alterations may
suppress the malignant phenotype. In the next 10 years,
the development of multiple methods for cancer therapy
can be envisaged as a rational approach to control of
neoplasia.
This manuscript was presented at the Conference on Biomonitoring
and Susceptibility Markers in Human Cancer: Applications in Molecular
Epidemiology and Risk Assessment that was held in Kailua-Kona,
Hawaii, 26 October-1 November 1991.
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